We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Opiant Pharmaceuticals Inc | NASDAQ:OPNT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.65 | 18.89 | 22.41 | 0 | 01:00:00 |
From May 2021 to May 2024
SANTA MONICA, Calif., April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC.
Opiant had no knowledge of the press release issued by Cision PR Newswire, and it is fake. Opiant and Hikma are not involved in any discussions of this type.
Cision PR Newswire issued a notice across its service confirming that journalists, investors and other readers should disregard the news release, "Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK" issued April 29, 2022, over Cision PR Newswire.
All further questions should be directed to Cision PR Newswire.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
Copyright 2022 PR Newswire
1 Year Opiant Pharmaceuticals Chart |
1 Month Opiant Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
